Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells

about

Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells

Item

http://www.wikidata.org/entity/Q58801325

description

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 03 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Pharmacologically upregulated ...... gainst colorectal cancer cells

@en

Pharmacologically upregulated ...... gainst colorectal cancer cells

@nl

type

Item

label

Pharmacologically upregulated ...... gainst colorectal cancer cells

@en

Pharmacologically upregulated ...... gainst colorectal cancer cells

@nl

prefLabel

Pharmacologically upregulated ...... gainst colorectal cancer cells

@en

Pharmacologically upregulated ...... gainst colorectal cancer cells

@nl

P1476

Pharmacologically upregulated ...... gainst colorectal cancer cells

@en

P2093

Chuan-Hsin Chang

http://www.w3.org/2001/XMLSchema#string

Hsu-Chao Hao

http://www.w3.org/2001/XMLSchema#string

Kwan-Hwa Chi

http://www.w3.org/2001/XMLSchema#string

Masayuki Shiozawa

http://www.w3.org/2001/XMLSchema#string

Mau-Shin Chi

http://www.w3.org/2001/XMLSchema#string

Yi-Ching Chen

http://www.w3.org/2001/XMLSchema#string

Yi-Chun Huang

http://www.w3.org/2001/XMLSchema#string

Yu-Shan Wang

http://www.w3.org/2001/XMLSchema#string

Yue-Cune Chang

http://www.w3.org/2001/XMLSchema#string

P2860

Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells

Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor

Toxicity and management in CAR T-cell therapy

Advantages and applications of CAR-expressing natural killer cells

Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process

Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92

Variable low dose rate irradiation (131I-anti-CEA) and integrated low dose chemotherapy in the treatment of nonresectable primary intrahepatic cholangiocarcinoma.

Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial.

NK cell-based immunotherapy for malignant diseases.

Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.

P2888

s12865-018-0262-z

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12865-018-0262-Z

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Satoru Takeda

P577

2018-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1105974169

http://www.w3.org/2001/XMLSchema#string

P698

30075754

http://www.w3.org/2001/XMLSchema#string

P921

immunology

Farmakologi

colorectal cancer

P932

6091054

http://www.w3.org/2001/XMLSchema#string